Dimebon – disappointing results in an Alzheimer’s disease trial, but hope remains for HD.
Advanced drug screening techniques help scientists to make drugs that increase cellular recycling in neurons.
Smaller total brain volumes in male HD mutation carriers suggests brain development may be different in HD.
Genetic evidence suggests connections between a polyQ disease and ALS (Lou Gehrig’s disease). Why should HD people ca
New data suggest there may be twice as many people with HD symptoms as previously thought – and even more at risk
Merger of two major Huntington’s Disease observational trials creates ENROLL-HD
Two clinical trials in Europe and the USA have suggested a new drug, Huntexil, might improve movements in HD. The nex
DOMINO clinical trial result: minocycline doesn’t slow down HD and shouldn’t be studied in larger trials.
The one-year report from the TRACK-HD study demonstrates a number of changes in pre-symptomatic HD-mutation carriers